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Abstract
Purpose To identify evidence-based indications for PET/PET–CT scans in support of facilities planning and to describe a 
pilot project in which this information was applied for an investment decision in an Austrian region. The study updates a 
Health Technology Assessment (HTA) report (2015) on oncological indications, extending it to neurological indications 
and inflammatory disorders.
Methods A systematic literature search to identify HTA reports, evidence-based guidelines, and systematic reviews/meta-
analyses (SR/MA) was performed, supplemented by a manual search for professional society recommendations and explicit 
“not-to-do’s”. A needs-assessment was conducted in the context of the pilot study on investing in an additional PET–CT 
scanner in the Austrian region of Carinthia.
Results Overall recommendations for indications as well as non-recommendations for the three areas (oncology, neurol-
ogy, and inflammatory disorders) were compiled from the 2015 PET–HTA report and expanded for a final total of ten HTA, 
comprising 234 (positive and negative) recommendations from professional societies and databases, and supplemented by 
findings from 23 SR/MA. For the investment decision pilot study in Carinthia, 1762 PET scans were analyzed; 77.8% were 
assigned to the category “recommended evidence-based indications” (54.7%), “not recommended” (1.8%) or “contradictory 
recommendations” (21.3%). The remaining could not be assigned to any of the three categories.
Conclusions The piloting of PET capacity planning using evidence-based information is a first of its kind in the published 
literature. On one hand, the high number of PET scans that could not be ascribed to any of the categories identified limits to 
the instructive power of the study to use evidence-based indication lists as the basis for a needs-assessment investment plan-
ning. On the other hand, this study reveals how there is a need to improve indication coding for enhanced capacity planning 
of medical services. Overall recommendations identified can serve as needs-based and evidence-based decision support for 
PET/PET–CT service provision.
Keywords Evidence-based planning · Needs-based planning · PET/PET–CT · Oncology · Neurology · Inflammatory 
disorders · Advanced diagnostics
Introduction
Europe is one of the largest markets for the fast-growing 
sector of medical devices (MDs) and diagnostic procedures, 
which encompass a broad and heterogeneous range of tech-
nologies. Due to the rising costs associated with introduc-
ing of new MDs and procedures into the healthcare system, 
payers have started to pay more attention to the effectiveness 
and financial implications of such new technologies. In this 
context, health technology assessment (HTA) has gained 
increasing recognition at the European level as a decision 
support tool [1].
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No other medical technology has been evaluated as fre-
quently by HTA institutions in European countries as “posi-
tron emission tomography (PET)”, or rather “positron emis-
sion tomography/computed tomography (PET/PET–CT)” [2, 
3]. In its 2015 assessment report [4] on PET/PET–CT, the 
Ludwig Boltzmann Institute for Health Technology Assess-
ment (LBI-HTA) aimed to capture the evidence base on 
oncological indications for a needs-based planning of PET/
PET–CT facilities in Austria. It identified around 160 assess-
ments on PET or PET–CT in a 10-year period (2004–2014), 
of which the first HTA were already published in 1995. This 
expresses uncertainty about the value of PET diagnostics 
in patient care. Notably, despite ongoing and controver-
sial discussions about the patient-relevant benefits of PET/
PET–CT, these technologies have rapidly been adopted both 
in Europe and abroad [2]. Additionally, the majority of those 
assessments is not accompanied by decisions regarding the 
reimbursement or planning of PET/PET–CT indications or 
devices. However, several approaches exist to deal with (to 
varying degrees) uncertain evidence or contradictory recom-
mendations around reimbursement and capacity planning 
in Europe and globally [4]. In practice, capacity planning 
employs a mix of different methods and methodological 
approaches such as comparative approaches (e.g., bench-
marking), analytical (e.g., health care needs-assessment) 
and/or reactive approaches (e.g., waiting lists). To provide 
volume forecasts for facility planning and workload vis-à-
vis PET/PET–CT, the number of patients with (sub-)indi-
cations is important as is the estimated number of patients 
eligible for therapy monitoring and radiotherapy dose plan-
ning. In addition, some special features of PET/PET–CT 
(e.g., required radionuclides/tracers) have to be taken into 
account. Yet the planning of capacities based on evidence-
based indications is rarely seen—neither in the literature 
nor in practice.
On the initiative of the German Society for Nuclear Medi-
cine (DGN), the LBI-HTA and the Department of Health 
Care Management at the Berlin University of Technology 
collaborated to (1) update the LBI-HTA 2015 report to iden-
tify indications recommended by evidence [HTA, systematic 
reviews/meta-analyses (SR/MA), evidence-based guidelines 
(EBG)] for PET/PET–CT scans supporting facility planning 
in Germany and Austria and (2) describe a pilot study which 
applied those recommendations identified in the evidence 
review from step (1) to an investment decision in the Aus-
trian region of Carinthia. The subsequent, updated, HTA 
report extended the scope of the 2015 report by including 
indications for neurology and inflammatory disorders in 
addition to oncological indications.
The following article summarizes both the results of the 
updated PET–HTA report, which has already been published 
(in German [5]), and the pilot study in Austria testing the 
practicalities of the recommendations.
Materials and methods
(1) Evidence‑based indications 
and recommendations
Sources of information, search strategy, and study selection
A systematic literature search was carried out in July 2017 
to identify HTA reports, SR/MA, and EBG to be included 
in the study. The databases MEDLINE, EMBASE, Pub-
Med, and Cochrane Library were searched using a search 
strategy retrieved from a published report by the Ger-
man Institute for Quality and Efficiency in Health Care 
(IQWiG), which was then updated and adapted [6]. A 
5-year window (2012–2017) for EBG and SR/MA was 
chosen [7]. HTA for the newly included indications (neu-
rology and inflammatory disorders) were limited to the 
last 10 years (2007–2017), while the most recent HTA 
[8–10] included in the PET–HTA report [4] were used 
for oncological indications, though oncological guidelines 
already included in the PET–HTA were updated if newer 
ones were available. Details about the searches are found 
in the Appendix A of the report [5] and a translated ver-
sion is found in the Online Resource 1 of this article.
The literature was screened in a two-stage process 
(First: title/abstract; second: full text) by two research-
ers of the author group. Inclusion and exclusion criteria 
were determined based on the criteria from the PET–HTA 
report 2015 [4] for consistency. English- and German-
language HTA, SR/MA, and EBG on the benefits of PET/
PET–CT were included, if they discussed (1) patient-rele-
vant benefits; (2) diagnostic accuracy/quality or change in 
patient management; (3) if they focused on one of the three 
indications/treatment areas (oncological and neurological 
indications, or inflammatory diseases); (4) were developed 
with an evidence-based methodology (e.g., a description 
of a literature search referenced more than two databases, 
inclusion/exclusion criteria and quality assessment, and 
double-check principle); and (5) were freely available. 
Differences in the assessment of literature were resolved 
through discussion and consensus building. A detailed 
overview of the criteria for inclusion and exclusion can 
be found in the Online Resource 2 of this article.
In addition to the systematic search, a supplementary, 
comprehensive manual search for evidence-based recom-
mendations on the use of PET/PET–CT was conducted. 
The selection of databases or websites [e.g., Cancer Care 
Ontario (CCO) and National Comprehensive Cancer Net-
work (NCCN)] was based on the PET–HTA report 2015 
[4] and complemented by relevant sources for the two new 
indications. The search could not be carried out in a sys-
tematic manner due to variation in search interfaces, but 
the search term PET was a common factor. Up-to-date 
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recommendations of the following national and suprana-
tional societies of nuclear medicine were included: Aus-
trian Society of Nuclear Medicine and Molecular Imag-
ing (ÖGN), German Society for Nuclear Medicine (DGN), 
Swiss Society for Nuclear Medicine (SGNM), European 
Association of Nuclear Medicine (EANM), Society of 
Nuclear Medicine and Molecular Imaging (SNMMI), and 
Joint Collaboration of EANM and SNMMI. Databases 
(e.g., Choosing Wisely, NICE Do-not-Do database) that 
explicitly identify “inappropriate” (not-to-do) services 
were also included as a source of information. Screening 
of documents from websites or professional societies was 
carried out by one person, with the extraction performed 
using the double-check principle. During the process of 
updating the HTA report, information sources were again 
scanned between January and February 2018.
Data extraction
Extraction tables were compiled separately for the three indi-
cations, using the double-check principle. In a first summary 
table, study characteristics were extracted separately, because 
they differ among HTA (e.g., reported endpoints and number 
of included studies), SR/MA (e.g., reference standard), and 
EBG (e.g., funding/sponsoring and strength of the evidence). 
Evidence derived from HTA and SR/MA was thus presented 
in the further tables including the evidence base and verba-
tim conclusions. The recommendations from EBG and web-
sites and databases of national and supranational societies 
were first extracted in tabular form and assessed along two 
dimensions: (1) appropriate use criteria and (2) inappropriate 
use criteria (e.g., suspension of decisions, recommendations 
based on insufficient evidence, and disinvestment recom-
mendations), including also the corresponding strength of 
the evidence. Recommendations of a certain level/strength 
of evidence (see Box 1) were then considered and clustered 
according to type and content of recommendations for further 
analysis into their similarities and differences.
Box 1: included professional societies 
and databases and the level/ strength of evidence 
taken into account for the recommendations
evidence hierarchy developed by the AANS/CNS 
Guidelines Committee (but no recommendation due 
to insufficient evidence)
• American College of Radiology (ACR): ACR Appro-
priateness  Criteria®: 7–9 = appropriate indications 
(4–6 = may be appropriate indications was not consid-
ered for the table, are available on request)*
• British Society for Hematology (BSH): GRADE was 
used to evaluate LoE and to assess the strength of rec-
ommendation (only A and B recommendations were 
considered)
• Canadian Association of Radiologists (CAR) Referral 
Guidelines: GRADE 1 = indicated, (“2 = Specialized 
Investigation” was not considered for this table, avail-
able on request)* & based on A (high-quality diag-
nostic studies such as studies in which a new test is 
independently and blindly compared with a reference 
standard in an appropriate spectrum of patients, etc.), 
B (lower case evidence in which the reference standard 
does not appear on all subjects, etc.), or C (studies in 
which the reference standard was not objective, expert 
opinion, etc.) were considered
• Cancer Care Ontario (CCO): LoE/GoR not indicated 
(only literature assigned to the recommendations)
• European Association of Nuclear Medicine (EANM)/
Society of Nuclear Medicine and Molecular Imaging 
(SNMMI): only Grade A and B considered
• European Federation of Neurological Societies 
(EFNS): good practice points not considered (lack of 
evidence but consensus by expert reached) and only 
recommendations for PET taken
• German Society for Nuclear Medicine (DGN): LoE/
GoR not indicated (only literature assigned to the rec-
ommendations)
• International myeloma Working Group (IMWG): LoE/
GoR according to OECBM (only A = Evidence of type 
I or consistent findings from multiple studies of types 
II, III, or IV and B = Evidence of II, III, or IV, findings 
are generally consistent) were considered
• Response Assessment in Neuro-oncology working 
group/European Association for Neuro-Oncology 
(RANO/EANO): only 1–3 LoE according to OCEBM 
included in their study (no information of LoE for the 
recommendations separately)
• Royal College of Radiologists and Royal College of 
Physicians (RCR/RCP): no LoE/GoR indicated (only 
literature assigned to the recommendations)
• Ryken et al.: evidence hierarchy developed by the 
AANS/CNS Guidelines Committee (level III = Clini-
cal uncertainty (inconclusive or conflicting evidence 
or opinion)
Level and strength of evidence considered for appro-
priate use:
• American College of Chest Physicians (ACCP): own 
grading system (only 1B recommendation available; 
grade 1B = strong recommendation, moderate quality 
evidence)
• American Association of Neurological Surgeons 
(AANS)/Congress of Neurological Surgeons (CNS): 
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• SNMMI/Alzheimer’s Association (AA): no LoE/GoR 
indicated (only literature assigned to the recommenda-
tions)
• SNMMI + EANM and American College of Nuclear 
Medicine (ACNM), American College of Preventive 
Medicine (ACPM), American Society of Clinical 
Oncology (ASCO), Canadian Association of Nuclear 
Medicine (CANM), and Society for Pediatric Radiol-
ogy (SPR): 7–9 = appropriate indications (4–6 = may 
be appropriate indications which were not considered 
for this table, available on request)
• National Comprehensive Cancer Network (NCCN): 
only LoE category 2A was considered (= based on 
lower level evidence, there is uniform NCCN consen-
sus that the intervention is appropriate; LoE 2B avail-
able on request; LoE 1 was not indicated for any of the 
recommendation)* & only ‘preferred’ recommenda-
tions were considered
Level and strength of evidence considered for inap-
propriate use:
• ACR: 1–3 = not appropriate (4–6 = may be appropri-
ate indications was not considered for the table, are 
available on request)*
• Choosing Wisely USA (ChW) and NICE Do-not-Do 
database: respective recommendations (both without 
“ratings”) were evaluated
• CAR: GRADE 5 = not indicated (GRADE 3 = not indi-
cated initially, 4 = indicated only in specific circum-
stances were not considered for this table, available on 
request) based on A, B, and C LoE (see above)*
• European Crohn’s and Colitis Organization/European 
Society of Gastrointestinal and Abdominal Radiology 
(ECCO/ESGAR): OECBM LoE 1–3 considered
• NCCN guidelines provide no separate category for 
inappropriate use; all guidelines were searched manu-
ally for information on inappropriate use/insufficient 
evidence
• BSH, CCO, CNS/AANS, EANM/SNMMI, EFNS, 
IMWG, RANO/EANO, RCR/RCP, Ryken, and 
SNMMI/AA: see information above on appropriate use
LoE level of evidence, GoR grade of recommendation
* Mainly due to the large amount, only those recom-
mendation from ACR, CAR, and NCCN with a cer-
tain level of recommendation were taken into account
Table 1  Colour coding of recommendations and level of contradictions between the evidence sources for the overall recommendations table
Classificaon of 
recommendaons  
"Yes" (indicaon to use, PET/PET-CT as primary treatment)
"No" (no indicaon to use, insufficient/inconclusive evidence)
"Restricted Use" (only as second-line or connuave method within an indicaon) 
"Unclear" (no concrete or contradictory recommendaons) 
Level of  
contradicons 
between the 
evidence sources  
Consensus of 
sufficient 
evidence in 
favour of 
PET/PET-CT  
Consensus of 
not sufficient 
evidence in 
favour for 
(against) 
PET/PET-CT 
Divergent 
statements 
(HTA vs. EBG vs. 
SR/MA) or 
contradictory 
results 
Divergent 
statements 
between EBG 
or 
contradictory 
results 
Recommendaon 
derived only from 
one source (HTA 
or EBG) 
Synthesis of recommendations
A summary of the recommendations derived from each of 
the three source types (HTA, EBG, SR/MA) was structured 
according to their indication. These are presented below. 
Based on the PET–HTA report 2015 [4], a classification 
of the recommendations into the categories “Yes”, “No”, 
“Restricted Use”, and “Unclear” was applied (Table 1). A 
color system shows the level of contradictories between the 
evidence sources (HTA, EBG, and SR/MA) regarding the 
respective recommendations and the strength of evidence. 
For oncological indications, recommendations from the 
PET–HTA report 2015 are included as well. 
Quality assessment
The quality of the included information sources was 
appraised by appropriate and validated tools, depending on 
the respective sources. The quality of HTA was assessed via 
a double-check approach supported by a checklist from the 
International Network of Agencies for Health Technology 
Assessment (INAHTA [11]) of 14 questions answered with 
“yes”, “partly”, and “no” (no total score). The AGREE II 
instrument (German version [12]) was used to assess the 
quality of EBG. Each guideline was evaluated by three inde-
pendent reviewers across six domains and a total of 23 items 
on a seven-point scale. It was determined that reviewers 
would deviate a maximum of two points in their final evalu-
ations. In the event of a discrepancy of more than two points 
per item, the questions were discussed and a consensus was 
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reached. The EBG were finally re-evaluated in their entirety 
resulting in an average score for each guideline. The SR/
MA were assessed by two reviewers independently with 
AMSTAR-2 [13], comprising a questionnaire consisting of 
16 yes/no questions. Discrepancies were resolved by consen-
sus. Overall quality was determined primarily by consider-
ing the critical questions (defined by the developers of the 
instrument [13]) and by allocating each SR/MA into one of 
four suggested categories (high, moderate, low, and critically 
low) [13]. For more details on the methods used, see the full 
report and the corresponding Appendix C [5].
(2) Pilot study: evidence‑based PET/PET–CT 
planning
A study was carried out to guide the investment decision for 
an additional PET–CT scanner in the region of Carinthia 
in Austria (561,000 inhabitants). First, a needs-assessment 
based on a data analysis of PET scans was conducted. Diag-
noses were coded according to the International Statistical 
Classification of Diseases and Related Health Problems 
 10th revision (ICD-10, 2016 [14]). All PET scans per-
formed from January to September 2017 were retrieved 
and clustered according to disease diagnosis (e.g., tumour 
type: C.00; malignant neoplasm of lip) and, if available, to 
subgroups of indications (e.g., C00.1 external lower lip). 
The information was then matched to identify recommenda-
tions for evidence-based indications or non-indications [see 
step (1)]. Indications with contradictory recommendations 
were—due to lack of detailed clinical information—ascribed 
to the category of dissenting or unclear evidence from HTA 
and/or guidelines. The categorization as well as the match-
ing with evidence-based indications was performed by two 
researchers.
Records identified through database searching
(n= 10.873), no time limit
MEDLINE (n= 5.975), Embase (n= 3.465)
PubMed (n= 858), Cochrane Library (n= 539)
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
fi
ca
o
n Additional records identified 
through other sources 
(n= 27)
Duplicates removed
(n= 2.729)
Records screened*
(n= 8.144)
Records screened (Title/Abstract) (n= 3.845)
Records excluded
(n= 3.412)
Full-text articles assessed for eligibility
(n= 433)
HTA (n= 32), EBG (n= 31)
SR/MA (n= 370) 
Full-text articles excluded, 
with reasons (n= 390)**
HTA: HTA not (freely) available/ not 
found (n= 11), language (n= 9), no 
PET/PET-CT Fokus (n= 2)
EBG: No EbM method used (n= 11),
broad spectrum (n= 2),
no PET/PET-CT focus (n= 1), indication 
(n= 1), further (n= 3)
SR/MA: Country (n= 146), 
no EbM method used (n= 98), study 
type (n= 64), no PET/PET-CT focus (n=
20), research question (n= 8), further 
(n= 14)
Studies included in qualitative synthesis
(n= 43)
Overall: HTA (n= 10), EBG (n= 13), 
SR/MA (n= 20), 
+ Update: HTA (n= 0), EBG (n= 1), 
SR/MA (n= 3)
Records excluded
(n= 4.299)
HTA u. SR/MA < 2007 (n= 1.742), 
EBG < 2012 (n= 2.557)
Fig. 1  PRISMA flowchart: study selection process of the systematic search [5]. *Due to the large amount of records identified, a time limit was 
set up for the title/abstract screening of SR/MA. **Online Appendix D [5] contains a list of excluded articles with reasons
70 Clinical and Translational Imaging (2019) 7:65–81
1 3
Results
(1) Evidence‑based indications 
and recommendations
Results of the evidence selection process
The systematic search yielded 10,873 references (Fig. 1). 
After the removal of duplicates (2729 references) and the—
ex post—introduction of a time limit (due to an enormous 
amount of materials), 4299 references were ultimately 
excluded and 3845 references remained for the two-step 
screening. Of these, 3412 references were excluded accord-
ing to the inclusion and exclusion criteria, leaving 433 full 
texts, 43 of which were finally included (10 HTA reports, 20 
SR/MA, and 13 EBG). An overview of the excluded refer-
ences (n = 390) with reasons can be found in the Appendix 
D of the updated HTA report [5]. The screening of the col-
lected alerts of the database searches (update: from July to 
December 2017) resulted in three more HTA, one EBG, and 
three SR/MA. As such, a total of 47 references were included.
The updated search results in guideline databases and 
websites and databases of relevant national and suprana-
tional societies regarding recommendations (see tables in 
report [5]) was compared with the results of the system-
atic research and the PET–HTA Report 2015, resulting in 
additional “appropriate use” recommendations from seven 
professional societies: DGN and the joint collaboration 
between EANM and SNMMI, RCP/RCR, ACR Appro-
priateness  Criteria®, CAR Referral Guidelines, and two 
oncology expert networks for guideline development, CCO 
and NCCN. It also resulted in concrete “not-to-use” recom-
mendations from four societies or databases: ACR, CAR, 
and the two disinvestment databases Choosing Wisely and 
NICE Do-not-Do database. Thus, a total of ten HTA, and 
234 positive and negative recommendations from profes-
sional societies and databases were included, supplemented 
by the statements from 23 SR/MA.
Evidence on oncological indications
Study characteristics
The PET–HTA report (2015) included 35 HTA assessments 
on 20 oncological indications. In addition, the report update 
revealed two novel HTA on bronchial carcinoma from the 
US Agency for Healthcare Research and Quality (AHRQ) 
[15] and the HTA-Center for the Västra Götaland Region, 
Sweden [16] as well as one HTA each on mamma carci-
noma, compiled also by AHRQ [15], on penile/testicular 
carcinoma and on bladder/renal cancer, the latter two com-
piled by the Scottish Health Technologies Group within 
Healthcare Improvement Scotland (SHTG/HIS [17–20]). For 
further oncological indications considered in the PET–HTA 
report 2015, no more recent HTA was found. Reported end-
points in the included studies used for the HTA reports refer 
to diagnostic accuracy (mainly tumour grading and change 
in management).
Recommendations as well as non-recommendations 
(n = 188) from professional societies (see Box 1 for abbrevia-
tions) were retrieved and extracted from AANS/CNS [21], 
ACCP [22], BSH [23], CCO [24–26], DGN [27], IMWG 
[28], and RCR/RCP [29]. Three common guidelines, one from 
SNMMI/EANM and others (ACNM, ACPM, ASCO, CANM, 
and SPR) [30], one from RANO/EANO [31], and one from 
EANM/SNMMI [32], were also considered. One guideline 
(Ryken et al. [33]) has been elaborated by several universities.
Three guidelines (CCO [24], RCR/RCP [29], SNMMI/
EANM/others [30]) provided recommendations for tumours 
generally as well as for non-oncological indications. Another 
three guidelines dealt with tumours of the head (DGN [27], 
Ryken [33], RANO/EANO [31]); two focused on myeloma 
(BSH [23], IMWG [28]); and one guideline addressed pros-
tate cancer (EANM/SNMMI [32]), anal canal carcinoma 
(CCO [25]), lung carcinoma (ACCP [22]), paraneoplas-
tic syndrome (PNS) (CCO [26]), and pituitary adenoma 
(AANS/CNS [21]), respectively. The recommendations of 
ACR [34], CAR [35] and NCCN [36] as well as the explicit 
non-recommendations of choosing Wisely [37] and NICE 
Do-not-Do [38] were also considered.
Moreover, 12 SR/MA for seven oncological sub-indica-
tions were included [39–50]; of those, two supplemented an 
HTA report [49, 50] and all considered diagnostic accuracy 
as an endpoint, especially for primary diagnosis and stag-
ing for pre-treatment/treatment planning. The systematic 
reviews consisted primarily of retrospective studies.
Quality assessment
The quality of the HTA was overall very good, with only 
a few questions not evaluated with “yes”. The assessment 
of the quality of the guidelines varied. In domain 1: “scope 
and purpose” and domain 4: “clarity of presentation”, the 
guidelines received high ratings and there were fewer varia-
tions among the guidelines. Domain 3 (“rigour of develop-
ment”), which considers the accuracy of guideline develop-
ment, ranged from 11% (DGN [27]) to 93% (ACCP [22]), 
showing the largest differences among the guidelines. In the 
overall rating, the ACCP guideline [22] was given a score of 
5.67 (max. 7) and also ranked highest among two domains 3 
and 4. The RCR/RCP guideline [29] attained last place with 
a mean score of 2.67.
The quality of the SR/MA in terms of overall qualitative 
assessment (no overall score) revealed that 10 out of 12 were 
“critically low”. Hence, the SR/MA is used only as supple-
mentary information.
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Table 2  PET/PET–CT indications (oncology): overall recommendations
RU (2)b,d D/S pulmonary & thoracic nodule (specific cases described by ACR, CAR)
No (3)b,e,o D/S pulmonary nodule (specific cases described by ACR)
TM (roune surveillance + follow-up)SCLC/NSCLC
TP (roune use outside research seng) SCLC/NSCLC
Unclear 
(4) a,e,n,o
Contradictoryrecommendaon: 
R/R SCLC/NSCLC: Yes (SNMMI/ACCP) vs. insufficient evidence (CCO)
TM (response evaluaon) SClC: Yes (SNMMI) vs. No (NCCN)
EsophagealCa
No* No recommendaon due to insufficient 
evidence
RU* Just as connuave diagnoscs, contradictory
Yes (2)e,l Re-/Staging before therapy/treatment TM (treatment response): 
pot. usefulUnclear 
(3) e,l, o
Contradictory recommendaon: 
R/R (suspected recurrence): RU (RCR/RCP) vs. insufficient evidence (CCO) 
TM (treatment response): Yes (NCCN) vs. insufficient evidence (CCO)
GastricCa
No* Scarce evidence No* No appropriate use criteria No HTA/GL/SR/MA idenfied (Update)
PancreacCa
RU* Inconclusive evidence, pot.diagnosis RU* Contradictory recommendaon 
No (2)d,e Primary diagnosis 
R/R (re-staging), TP (treatment response), TM (guide clinical management) pancreac 
adenocarcinoma  insufficient evidence
Unclear 
(3)d,e,l
Contradictoryrecommendaon: 
Staging before curave surgical resecon: Yes (CAR, CCO) vs. RU (RCR/RCP)
LiverCa 
No* Weak (scarce) evidence No* No appropriate use criteria
Yes (1)l 11C- Choline, 18F-fluoro-choline, Ga-PSMA, 11C-Acetate: TP HCC
RU (2)d,l D/S, R/R hepato-(pancreaco)-billaryCa
D/S liver lesion 
No (2)b,o D/S (primary diagnosis) HCC
D/S liver lesion (specific cases described by ACR)
TP (roune use pre- operave) –
–
insufficient evidence
AnalcanalCa
No (1)e D/S (roune invesgaon), R/R & TM analcanalCa –insufficient evidence
•
–
HTA (n) Notes EBG (n) Notes Addional informaon from SR/MA
Brain Tumor
No* No recommendaon, weak evidence RU* Contradictory recommendaon (glioma)
RU (2)h,l D/S (grading tumor, disng. WHO grades, differenal diagn. of tumor/glioma) Primary diagnosis (brain tumor, 
glioma): 18FET-PET higher 
diagnosc performance than FDG
PET (Grading: no difference 
between tracer) 
RU (3) h,k,l Amino Acid: D/S (grading tumor), R/R + TM
No (4)b,e,k,m D/S & TP (glioma)
Roune use (brain metastases & glioblastoma)
Follow-up (specific case described by ACR)
R/R + TM (glioma) - insufficient evidence
Unclear (2)k,l Contradictory recommendaon: 
TP (glioma): RU (RCP/RCR) vs. RU (RANO/EANO: not grade III/IV glioma)
Head and NeckCa
RU* Some evidence, Re-/Staging + Thyroid RU* CUP, Thyroid, contradictory for other Ca
RU (5)b,d,e,l,n D/S (+ CUP), R/R (local recurrence, metastases) + TP head and neckCa
TM (response evaluaon) Head and NeckCa
R/R (suspected recurrence) thyroid
R/R (residual disease) parodCa (problem solving tool) 
11C-Menthione: D/S (localizaon) parathyroidCa (difficult cases) 
No (2)b,d D/S head and neckCa (specific cases described by ACR)
Staging (I or IIA/B) thyroidCa
MammaCa
No* Inconclusive evidence No* No appropriate use criteria, pot. diagnosc of recurrence 
Yes (1) 18F-FET:
MammaCa (mainly bone metastases)
Yes (2)l,n TM (treatment response) bone metastases D/S: Beer diagnosc 
performance for distant 
metastasis staging of whole- body 
18F -FDG-PET/PET- CT compared to 
convenonal imagining
Yes (3)b,l,n R/R (suspicion of metastac disease, local recurrence) known 
breast cancer/dense breast
No (5)b,e,f,o,p D/S (specific cases decribed by ACR, e.g. high risk paents)
D/S (staging)
TM (monitor) advanced breast cancer 
BronchialCa – Update: Thorax/LungCa
RU* Some evidence Re-/Staging RU* Different sub-indicaons, less contradictory
Yes (1) 18F-FDG:Pre-treatment staging 
of SCLC 
Yes (4)b,d,e,l 18F-FDG:Pre-treatment staging SCLC/NSCLC (curave intent), thymic tumor, pleural 
malignancy
Yes (1) 18F-FDG:TP (prior to dose planning) 
SCLC/NSCLC
•
•TM (tumor response) metastac 
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Table 2  (continued)
HTA (n) Notes EBG (n) Notes Addional informaon from SR/MA
ColorectalCa
RU* Some evidence Staging/Recurrence RU* Remote metastases/Re-staging/Therapy monitoring
less contradictory
RU (4) d,e,l,n D/S (staging) only in selected cases (problem solving tool)
Less contradictory
R/R (re-staging (recurrence)), TP (therapy planning, monitoring)
Highly accurate for detecon of 
liver metastases in PT with 
ColorectalCa, more specific than 
PET/MRI
Affects changes in 
PT management
No (4) d,e,f,o D/S (roune use)
TM (roune surveillance)
BladderCa
No* Scarce/inconclusive evidence No* No appropriate use criteria
No (1) Scarce evidence (D/S, R/R) No (3)b,d,o D/S bladder/urothelialCa + TM superficial TCC 
Yes (1)l TP (curave intent) advanced muscle-invasive bladderCa
RenalCa
No* Scarce evidence No* No appropriate use criteria
Unclear 
(1)
R/R (disease recurrence or metastases) 
insufficient evidence
RU (1)l D/S (staging) (metastac) renal (ureteric)Ca
UtericCa
No* Scarce evidence No* No appropriate use criteria
Yes (2)d,l Re-/staging utericCa (radical intent)
RU (2)b,d R/R (recurrence) endometrialCa
CervicalCa
RU* Some evidence Staging/Recurrence No* No appropriate use criteria, pot. for locally advanced Ca
Yes (2)d,l Re-/staging (radical chemotherapy) locally advanced cervicalCa 
TP (pelvic exenteraon/chemoradiaon, curave intent)
RU (2)b,l R/R (recurrence) cervicalCa
TM (aer chemoradiotherapy) locally advancedCa
No (2)b,e TM (follow-up) specific cases described by ACR, aer chemotherapy 
Unclear (1)e )gnigats(S/D insufficient evidence
OvarialCa
No* Scarce/inconclusive evidence No* No appropriate use criteria
Yes (1)b R(R (recurrence) loco -regional and distant disease 
RU (1)l D/S (detecon of tumor) rising CA125 level
−
No (2)b,e D/S (diagnosis) 
D/S (staging), specific cases (high risk) described by ACR
R(R (recurrence, re-staging) not considered for surgery 
TP (PT considered for secondary cytoreducon) – insufficient evidence
TescularCa
No* Inconclusive evidence No* No appropriate use criteria
No (1) D/S (staging), R/R (re-staging) –
insufficient evidence
RU (3)d,e,l D/S (M staging) 
R/R (recurrence)
TM (treatment response) seminoma
No (1)e R/R (roune use) – insufficient evidence
TM (treatment response) nonseminoma
ProstateCa
No* Not indicated No* No appropriate use criteria
RU (2)h,l 11C-Choline, 18F-fluoro-choline, 68Ga-PSMA: Pre-treatment staging 
in high-risk PT + recurrence 
11C-Choline, 68Ga-PSMA:  pre-
treatment staging + recurrence 
(GA-PSMA-favorable)
18F-FACB: R/R  (pot. tool for 
recurrence)
No (2)b,f D/S, TM (specific cases described) 
PenilCa
No* Not indicated No* No appropriate use criteria
Yes (1)l Pre-treatment staging 
No (1) D/S (staging) R/R (re-staging) PenileCa –
insufficient evidence
Musculosceletal and so ssue CA (+GIST)
No* No final recommendaon possible RU* Biological aggressiveness before surgery, GIST
Yes (2)l,n D/S (staging), TP (pre-amputaon) high grade sarcoma 
R/R (recurrence) sarcoma 
D/S, TP (pre-treatment staging), R/R (treatment response) GIST
RU (2)b,l D/S, R/R musculoskeletal tumor (specific cases described by ACR)
D/S metastac sarcoma suitable for metastasectomy
18F-fluoridebone imaging : D/S benign malignant bone disease
No (1)b D/S so ssue masses and musculoskeletal tumor (specific cases described by ACR)
Unclear 
(3)b,l,n
Contradictory recommendaon: 
D/S osteosarcoma: Yes (RCR/RCP) vs. No 
(specific case described by American College of Radiologists)
TM (treatment response): Yes, sarcoma (SNMMI) vs. 
Yes, but only for high grad sarcoma RCR/RCP
•
•
•
•
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Overall recommendations
Table 2 provides an overview of the overall recommenda-
tions on oncological indications (see also Table 1 for the 
explanation of colors and categories).
There is a (relative) consensus that there is sufficient 
evidence for sub-indications in eight indications in favour 
of PET or PET–CT examinations (in Table 2 highlighted 
green). The first six were already determined in the 2015 
report—(1) bronchial carcinoma (update: mainly pre-
treatment, contradictory in re-staging and response con-
trol and in therapy monitoring), (2) colon carcinoma, (3) 
malignant lymphoma, (4) malignant melanoma (update: 
contradictory for diagnosis of recurrence), (5) mamma car-
cinoma (treatment response, for diagnosis of recurrence), 
and (6) head–neck tumours (in 2015 report: CUP, thyroid 
carcinoma; update: mainly for diagnosis of recurrence)—
while two new treatment areas were added by the update: 
(7) myeloma and (8) neuroendocrine tumours.
There is a (relative) consensus that, in eight other indi-
cation areas, there was too little evidence in favour of PET 
examination (individual decisions possible) (in Table 2 
highlighted red): (1) bladder carcinoma, (2) hepatic can-
cer, (3) cervical carcinoma, (4) gastric cancer, (5) ovar-
ian and (6) uterus carcinoma, (7) prostate cancer, and (8) 
paraneoplastic neurological syndrome.
Table 2  (continued)
Medical indicaons not reported in LBI-HTA report
All tumors
RU (2)d,l D/S (specific cases described) oligometastac disease + CUP
No (3)d,f,g R/R, roune surveillance + screening healthy individuals
TP adenoma
Myeloma
Yes (3)c,j,l D/S, R/R, TM (specific cases described) 
No (2)b,l D/S (roune use)   insufficient evidence
D/S mulple myeloma (specific case decribed)
Neuroendocrine tumor
Yes (1)l D/S, R/R (re-staging), TP paraganglioma 68GA-DOTATATE PET more sens. 
& spec. than 68GA-DOTATOCYes (1)l 68Ga-labelled SSR: D/S (staging), R/R (recurrence)
18F-FuoroDOPA: D/S (selected paents)
RU (1)l TP (pre-treatmant) adrenocorcalCa
No (1)o TM (surveillance) 
•
–
HTA (n) Notes EBG (n) Notes Addional informaon from SR/MA
Lymphoma 
RU* Some evidence 
Interim-/Re-/Staging/Recurrence
RU* Different sub-indicaons
Yes (4)d,e,l,o D/S e.g. castelman’s disease
TM (treatment response)
PET-based treatment assessment 
should be considered in the 
management of PT with follicular 
lymphoma (post-chemotherapy 
response assessment)
RU (2)e,l D/S, TP HL/NHL
No (4)b,e,l,p TM (monitoring + surveillance) roune use HL/NHL
Unclear 
(4)d,e,l,n
Contradictory recommendaon: 
R/R (recurrent disease): RU (CCO, CAR) vs. Yes (RCR/RCO, SNMMI)
Melanoma
RU* Diagnosc accuracy depending on tumor 
grade
RU* Staging/Recurrence in higher stages, less contradictory
Yes (4)d,e,l,n D/S (staging) high-risk PT (advanced stages) with pot. resectable disease 
D/S (specific cases described, e.g. merkel -cellCa)
R/R (recurrence) 
Staging: beer diagnosc 
accuracy in high-risk PT
No (3)e,f,l D/S (roune use) primary uveal malignant melanoma
D/S (staging) I, IIa, IIb melanoma 
D/S (diagnosis) sennel lymph node micrometastac disease 
D/S localised primary cutaneous melanom
TM (treatment response, roune surveillance) – insufficient evidence
Unclear (2)l,n Contradictory recommendaon: 
TM (treatment response): Yes (SNMMI) vs. RU (RCR/RCP)
Paraneo-plasc syndrom (PNS)
No* Scarce evidence No* Not described 
RU (2)e,l D/S (specific cases described) 
•
•
Ca carcinoma, D/S diagnostic/staging, 18F-FDG fludeoxyglucose (18F), 68Ga-PSMA 68Ga-labelled prostate-specific membrane antigen, GoR 
grade of recommendation, GIST gastrointestinal stromal tumours, GL guidelines, HTA health technology assessments, LoE level of evidence, 
MRI magnetic resonance imaging, NHL non-hodgkin-lymphoma, NSCLC non-small cell lung cancer, PT patients, R/R recurrence/re-staging, RU 
restricted use, SCLC small cell lung cancer, TCC transitional cell carcinoma, TM therapy monitoring, TP therapy planning
*Recommendations from PET–HTA report 2015 [4]; color coding of recommendations and level of contradictories between the evidence 
sources: see Table 1; the number of HTA reports/guidelines is given in brackets; superscript letters indicate the respective guideline: a. ACCP, 
b. ACR, c. BSH, d. CAR, e. CCO, f. ChW, g. CNS/AANS, h. DGN, i. EANM/SNMMI, j. IMWG, k. RANO/EANO, l. RCP/RCR, m. Ryken, n. 
SNMMI, o. NCCN, p. NICE Do-not-Do; LoE/GoE for appropriate use/inappropriate use: see Box 1; information given in the table refer to FDG 
PET and PET–CT, and the use of other tracer are indicated in the table
74 Clinical and Translational Imaging (2019) 7:65–81
1 3
For a further set of eight indications, there is contradic-
tory and equivocal evidence and recommendations were 
developed along with reservations (in Table 2 highlighted 
yellow or blue): (1) anal canal, (2) brain (especially gli-
oma), (3) testicular, (4) renal, (5) penile carcinoma, (6) 
esophagus cancer (except re-staging), and (7) pancreatic 
carcinoma as well as (8) bone and soft-tissue tumour 
(+ gastrointestinal stromal tumour).
Evidence on neurological indications
Study characteristics
Two HTA reports were identified about neurological indi-
cations for the use of PET—one from the Australian Medi-
cal Services Advisory Committee (MSAC) [51] looking 
into Alzheimer’s dementia (AD) and one compiled by the 
Canadian Agency for Drugs and Technologies in Health 
(CADTH) on epilepsy [52]. Reported endpoints in the 
included studies of these HTA reports refer mainly to diag-
nostic accuracy; no study could be identified that investi-
gates diagnostic effectiveness and safety.
Recommendations and non-recommendations (n = 28) 
from professional societies (see Box 1 for abbreviations) 
were retrieved and extracted from CCO [24, 53], EFNS [54], 
RCR/RCP [29], SNMMI/AA [55], and a common guide-
line from EANM/SNMMI [56]. RCR/RCP [29] provides 
recommendations for several non- and oncological indica-
tions. Two further guidelines ([54, 55]) consider Alzheimer’s 
dementia/dementia (ADD) or AD only, while another guide-
line (EANM/SNMMI [56]) presents general recommenda-
tions on brain-related disorders (refer to SNMMI/AA [55]) 
CCO [24, 53] (two guidelines) which considers epilepsy. 
In total, three SR/MA were included (for AD) [57–59]. All 
consider diagnostic accuracy in terms of primary diagnosis 
as the endpoint. Primarily, prospective studies were included 
in the SR/MA.
Quality assessment
The quality of the HTA was rated as very good, with only 
one question not judged as “yes”. The assessment of the 
quality of the guidelines showed that domains 1 (“scope 
and purpose”) and 4 (“clarity of presentation”) received 
very high ratings and are quite consistent. However, in 
terms of editorial independence, applicability, and accu-
racy of the guideline development, big differences were 
observed. In the overall assessment, SNMMI/AA [55] 
ranks first; RCR/RCP is in last place [29]. All the SR/
MA rated “critically low” in the overall quality assess-
ment (no comprehensive score). As such, the SR/MA are 
to be used as supplementary information for the overall 
recommendations.
Table 3  PET/PET–CT indications (neurology): overall recommendations
HTA (n) Notes EBG (n) Notes Addional informaon from SR/MA
Alzheimer’s disease demena and any other form of demena/Mild cognive impairment (MCI)
No (1)f Routine use (Amyloid tracer) 
Evidence level unclear
No Routine use  (11C-PIB-PET, 18F-FDG 
PET)
Sensitivity & specificity of the three 
beta-amyloid radiotracers for 
quantitative and visual analysis are 
comparable to those with other 
imaging or biomarker techniques used 
to diagnose ADD 
No differences in the diagnostic 
accuracy of the three beta-amyloid 
radiotracers
RU (4)d,e,f,g 18F-labelled Amyloid (Florbetaben, Flutemetamol, Florbetapir, 
NAV4694) and 18F-FDG PET, PET-CT: 
D/S: PT with specific characteristics and cases described 
(different for the tracer*)
Less contradictory, but based on weak evidence
No (5)a,c,d,f,g 18F-labelled Amyloid (Florbetaben, Flutemetamol, 
Florbetapir, NAV4694) and 18F-FDG PET, PET-CT: 
D/S: PT with specific characteristics and cases described 
(different for the tracer*)
Less contradictory, but based on weak evidence
Unclear (1) 18F-FDG PET, PET-CT:
Diagnostic quality – able to detect temporoparietal 
changes with high degree of accuracy; marginally 
superior at identifying midly affected brain regions 
(compared to SPECT) – no concrete recommendation 
given
Epilepsy (seizures)
No (1) Pre-surgical evaluation 
(pot. useful in conjuction with other imaging 
modalities)
RU (3)a,b,f Pre-surgical evaluation (specific cases described*), 
setting: spec. epilepsy centres
Less contradictory, but evidence level only given by ACR (7)
No (2)a,b D/S: specific cases described, e.g. new-onset seizure, 
neonatal seizures 
D/S: PT with intractable infantile spasms after inconclusive 
initial diagnostic – insufficient evidence 
•
•
•
ADD Alzheimer’s disease dementia, 11C-PIB 11C-Pittsburgh compound B radiotracer, D/S diagnostic/staging, FDG 18F-Fluordesoxyglucose 
radiotracer, GL guidelines, GoR grade of recommendation, HTA health technology assessment, LoE level of evidence, MA meta-analysis, PT 
patients, RU restricted use, SR systematic reviews
*See PET–HTA report 2018 [5] for detailed cases; color coding of recommendations and level of contradictories between the evidence sources: 
see Table 1; number of HTA reports/guidelines is given in brackets; superscript letters indicate the respective guideline: a. ACR, b. CCO, c. 
ChW, d. EANM/SNMMI, e. EFNS, f. RCP/RCR, g. SNMMI/AA; LoE/GoE for appropriate use/inappropriate use: see Box 1; information given 
in the table refer to FDG PET, PET–CT, and the use of other tracer are indicated in the table
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Overall recommendations
For recommendations of neurological indications, evidence 
identified and presented only two sub-indications: Alz-
heimer’s dementia/dementia and epilepsy (see Table 3 for 
details).
There is a (relative) agreement that there is not sufficient 
evidence in favour of a PET/PET–CT for either of these 
two sub-indications (in Table 3 highlighted red), though 
professional societies uniformly/consistently name specific 
cases of AD or specific patient characteristics that speak for/
against the use of PET, depending mainly on the respective 
tracer (amyloid vs. FDG). These recommendations, how-
ever, are only based on one source [55, Update: 60] and 
the authors themselves acknowledge the limitations, stating 
that, “At the time of this review, experience with clinical 
amyloid PET imaging [was] limited. Most published stud-
ies to date … [were] designed to validate this technology 
and understand disease mechanisms rather than to evalu-
ate applications in clinical practice. As a result, published 
data are available primarily from highly selected popula-
tions with prototypical findings rather than from patients 
with comorbidities, complex histories, and atypical features 
often seen in clinical practice (e7)” [55].
Equivocal evidence (e.g., contradictory between HTA and 
EBG in Table 3, highlighted yellow or blue) was also found 
for the application of PET/PET–CT in patients having epi-
lepsy (again, only in certain cases, in specialized epilepsy 
centres), though there is (some) consensus among the pro-
fessional societies.
Evidence on inflammatory disorders
Study characteristics
In total, three HTA could be included about inflammatory 
disorder indications. One focused on infections in general 
from CADTH [61], dating back to 2008, and two other 
reports (each consists of a scoping report and an advice 
statement) from SHTG/HIS (2013) focus on pyrexia of 
unknown origin and sarcoidosis [62–65]. Reported end-
points in the studies within these HTA reports refer to diag-
nostic accuracy (mainly for primary diagnosis).
Recommendations and non-recommendations (n = 18) 
from professional societies (see Box 1 for abbreviations) 
were retrieved and extracted from ECCO/ESGAR [66], a 
common guideline of EANM/SNMMI [67] and RCR/RCP 
[29] who gave recommendations for several non-oncologi-
cal indications. EANM/SNMMI [67] gave general recom-
mendations on inflammatory disorders and ECCO/ESGAR 
[66] considers inflammatory bowel disease alone. Explicit 
non-recommendations by Choosing Wisely [37] or NICE 
Do-not-Do [38] were not identified.
In total, eight SR/MA were included for five indications 
[68–75]. All but two reviews [68, 69] include a meta-analysis 
and consider diagnostic accuracy as the primary endpoint.
Quality assessment
The quality of the three HTA was rated “very good”, with 
only a few questions that could not be judged “yes”. And 
the quality of the three guidelines revealed that domain 3 
[on the rigour of the guideline development (including evi-
dence clearly assigned to recommendations)] ranges widely, 
from 16% (RCR/RCP [29]) to 55% (ECCO/ESGAR [66]). 
Notably, all guidelines were rated 0% with regard to edito-
rial independence (domain 6). The RCR/RCP [29] guideline 
scored poorest on in all areas compared to the other two. In 
the overall rating, ECCO/ESGAR [66] ranked first of the 
guidelines and all SR/MA were rated as “critically low”.
Overall recommendations
Table 4 shows the overall recommendations regarding the 
appropriate or inappropriate use of PET/PET–CT for inflam-
matory disorder indications. There is (relative) consensus 
around sufficient evidence in favour of PET or PET–CT for 
infections of the vertebral column/spondylodiscitis. For the 
following four sub-indications, however, there is contradic-
tory or inconclusive evidence: periprosthetic joint infection, 
osteomyelitis, sarcoidosis, and fever of unknown origin.
(2) Pilot study: evidence‑based PET/PET–CT 
planning
In a second step, the recommendations derived from the 
evidence were applied (matched) to the hospital data on 
PET scans in one hospital (Carinthia, Austria) to gain an 
understanding of the PET utilization and capacity needs. 
Between January and September 2017, 1762 PET scans were 
conducted at the Clinicum Klagenfurt/Carinthia (KABEG 
Management: Needs-assessment of PET–CT at the Clinicum 
Klagenfurt, June 2018, unpublished). Of those, 1370 (77.8%) 
could be assigned to the three categories (see Tables 1–4) as 
recommended by evidence-based indications (963, 54.7%), 
not recommended (311.8%) and contradictory recommenda-
tions (376, 21.3%). The other 392 (of 1762, 22.2%) could not 
be allocated to any of the three treatment areas due to miss-
ing information of the diagnostic code or lack of information 
from recommendations in HTA or clinical guidelines.
A systematic analysis of all 1762 PET scans was not 
possible for two reasons: first, all ambulatory patients who 
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underwent a PET scan were coded with a non-specific 
diagnostic code (such as ‘other’ investigation), so that the 
underlying reasons for PET diagnosis could not be identified 
and, second, no diagnostic code was assigned to in-patients 
transferred for the PET scan from the other Carinthian hos-
pitals. Of the 963 PET scans that were possible to match to 
evidence-based recommendations (see Table 5), four ICD-
10 tumour categories alone accounted for 79%: C30–C39: 
Table 4  PET/PET–CT indications (inflammatory indications): overall recommendations
HTA (n) Notes EBG (n) Notes Addional informaon from SR/MA
Immune-compromised PT/problemac cases
Yes (1)d D/S: site of focal infecon
Infecve endocardis (nave valve)
Currently not sufficient for the diagnosis of infecve endocardis 
because of its low sensivity
Infecve endocardis related to intravascular devices, pacemakers, catheters or prosthec valves 
Unclear (3)a,b,d Post-surgery (aer a certain me)
vs. insufficient evidence/unclear
As a promising imaging modality (adjuncve diagnosc tool) in 
evaluang PT with suspected CIED infecon, PVE or IE in general
Should be considered in cases where the diagnosis is uncertain 
(PVE)
Inflammatory bowel disease
Unclear (2)b,c D/S: Poorly specific 
Invasive mould infecons
Yes (1) Helpful in clinical management
Limbic encephalis
Should be integrated with other clinical or imaging invesgaons 
(such as MRI)
Lung infecons
No (1)a Specific case described 
Mulple infecon indicaons 
Unclear (1) Diganosc quality – no recommendaon given
Musculoskeletal infecons – Charcots neuroarthopathy 
Yes (1) Grading 
Musculoskeletal infecons – Chronic extremity/back pain
No (1)a D/S: Specific case described
Musculoskeletal infecons – Chronic osteomyelis of the mandible
Yes (1) Follow-up
Musculoskeletal infecons – Infecons of vertebral column or spondylodiscis
Yes (1) Diagnosc quality – superior accuracy 
compared with other imaging methods
Yes (1)b D/S: non-postoperave Robust diagnosc test for suspected spondylodiscis
Musculoskeletal infecons – Joint (peri-)prosthec infecons (e.g. knee or hip implants)
•
•
•
•
•
Yes (1) Diagnosc quality – superior accuracy 
compared with other imaging methods
Unclear (2)a,b Contradictory recommendaon: 
Specific cases where it is not recommended 
vs. unclear (insufficient evidence) 
May not yet been the preferred imaging technique 
Musculoskeletal infecons – Osteomyelis of foot (related to diabetes)
No (1)a Specific case described As potenally useful tools if combined with other imaging 
methods
Musculoskeletal infecons – Osteomyelis 
Yes (1) Diagnosc quality – superior accuracy
compared with other imaging methods
No (1)a D/S: Specific case described 
PUO
No (1) Diagnosc quality – insufficient evidence RU (2)b,d D/S (primary diagnosis + diagnosc quality)
Sarcoidosis
No (1) Primary diagnosis (roune invesgaon) –
insufficient evidence
RU (2)b,d Specific cases (selected PT, 
aer conv. imaging) 
Vasculis
Yes (2)b,d Specific cases described
Further indicaons (no details given): Evaluaon of potenally infected liver and kidney cysts in polycysc disease; 
AIDS-associated opportunisc infecons, associated tumors, and Castleman disease; Assessment of metabolic acvity in tuberculosis lesions; Diabec foot infecons
Nob Based on insufficient evidence**
Further indicaons (no details given): Metastac infecon & of high-risk PT with bacteremia
Yesb Based on insufficient evidence**
•
•
AIDS Acquired Immune Deficiency Syndrome, AS anti-granulocyte scintigraphy, BMS bone-morrow scintigraphy, BS bone scintigraphy, CIED 
cardio-vascular implantable electronic device, D/S diagnostic/staging, FDG 18F-Fluordesoxyglucose tracer, GL guidelines, GoR grade of recom-
mendation, HTA Health Technology Assessment, LoE level of evidence, LS leukocyte scintigraphy, MA meta-analysis, MRI magnetic resonance 
imaging, PT patients, PUO Pyrexia of unknown origin, PVE prosthetic valve endocarditis, SR systematic reviews
*HTA report from 2008; **EANM/SNMMI: “Although there is still insufficient literature for this to be described as an evidence-based indica-
tion, we can conclude [major indications], on the basis of a cumulated reported accuracy (> 85%) and expert opinion…” and “Level of evidence 
available at this time for many of these indications remains insufficient to strongly advise the use of 18 F-FDG imaging as a first-line diagnostic 
tool.”; color coding of recommendations, and level of contradictories between the evidence sources: see Table 1; the number of HTA reports/
guidelines is given in brackets; superscript letters indicate the respective guideline: a. ACR, b. ECCO/ESGAR, c. EANM/SNMMI, d. RCP/RCR: 
LoE/GoE for appropriate use/inappropriate use: see Box 1; information given in the table refer to FDG PET, PET–CT, and the use of other tracer 
are indicated in the table
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malignant neoplasms, respiratory system, and intratho-
racic organs (273, 28%), C43–C44: malignant neoplasms, 
skin, (224, 23%), C81–C96: malignant neoplasms, stated 
or presumed to be primary, of lymphoid, haematopoietic 
and related tissue (177, 18%), and D37–D48: neoplasms of 
uncertain or unknown behaviour (99, 10%).
The majority (22, 70%) of the 31 PET scans not rec-
ommended within evidence-based recommendations (see 
Table 5) were in the following three ICD-10 indications: 
C64–C68: Malignant neoplasms, urinary organs (10, 32%), 
C15–C26: malignant neoplasms digestive organs (6, 19%), 
and C50–C58: malignant neoplasms, breast and female geni-
tal organs, respectively (6, 19%).
Discussion
Summary of findings: (1) evidence‑based 
indications and recommendations
Evidence assessments on PET/PET–CT have been increas-
ingly published over the past two decades in many coun-
tries and languages. Taking a 2004–2014 perspective, the 
PET–HTA 2015 report identified 155 HTA reports to evalu-
ate PET or PET–CT; even with a timeframe of 2008–2014, 
there were still 82 HTA available. Thirty-five of these were 
included and extracted for their statements on the use of 
PET/PET–CT for oncological indications. Five more recent 
HTA on oncological (sub-)indications were identified during 
the HTA report update. For the new indications—for neuro-
logical and inflammatory disorders—only five HTA could 
be considered. Recommendations of professional societies 
(e.g., guidelines) were also updated and explored for the 
three indications. A total of 234 recommendations were, 
therefore, included in the updated report. In addition, a total 
of 23 SR/MA provided supplementary information. Fifteen 
looked only at oncological indications. Cost-effectiveness of 
PETs was not an inclusion criterion and was, therefore, not 
explicitly considered; however, while almost no evidence 
exists, information was extracted from the reports when 
there was mention of cost-effectiveness.
In a comparison of HTA results, the tabulated recommen-
dations of professional societies and SR/MA for oncological 
indications reveal that there is general agreement on “sig-
nificant” indications (e.g., bronchial carcinoma, and head 
and neck tumours) for the use of PET/PET–CT. However, 
there are significant differences in the level of detail of sub-
indications and in the approach for when a scan should not 
be performed. There is also significant variance in the reli-
ance on the access of graded pre-diagnostics.
Between the current study and the 2015 PET–HTA report, 
several changes in the categorization of oncology indications 
and in level of contradictory among the evidence sources 
have occurred (below is an overview; see Tables 1, 2, 3, 4):
– Mamma carcinoma (now recommended for certain sub-
indications such as tumour response assessment for 
metastatic mamma carcinoma (mainly bone metastases), 
before: not recommended)
Table 5  PET scans and corresponding ICD-10 category matched to evidence-based recommendations (n = 994), Clinicum Klagenfurt/Carinthia 
(KABEG Management: Needs-assessment of PET–CT at the Clinicum Klagenfurt, June 2018, unpublished)
ICD-10 categories Recommended evidence-based 
indications
(n = 963), n (%)
Not recommended 
evidence-based indica-
tions
(n = 31), n (%)
C15–C26: malignant neoplasms, digestive organs 28 (3) 6 (19)
C30–C39: malignant neoplasms, respiratory system and intrathoracic organs 273 (28) –
C43–C44: malignant neoplasms, skin 224 (23) –
C50–C58: malignant neoplasms, breast, and female genital organs 67 (7) 6 (19)
C60–C63: malignant neoplasms of male genital organs – 2 (7)
C64–C68: malignant neoplasms, urinary organs – 10 (32)
C73–C75: malignant neoplasms, endocrine glands, and related structures 36 (4) 3 (10)
C76–C80: malignant neoplasms, secondary and ill-defined 5 (< 1) 1 (3)
C81–C96: malignant neoplasms, stated or presumed to be primary, of lymphoid, 
haematopoietic and related tissue
177 (18) –
D00–D09: in situ neoplasms – 1 (3)
D10–D36: benign neoplasms 52 (5) 2 (7)
D37–D48: neoplasms of uncertain or unknown behaviour 99 (10) –
G30–G32: other degenerative diseases of the nervous system 2 (< 1) –
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– Cervix carcinoma (not recommended, before contradic-
tory)
– Testicular, renal, and penis carcinoma (contradictory, 
before not recommended)
– New (not included in the PET–HTA report 2015): mye-
loma (recommended), neuroendocrine tumours not rec-
ommended), anal canal cancer (contradictory)
In the case of neurological indications and inflammatory 
disorders, there is comparatively more discrepancy in the 
recommendations of professional societies and between the 
HTA and professional societies. There is a notable, consist-
ent emphasis on the weak and insufficient evidence base. 
The SR/MA included in our report demonstrate this: all were 
considered “critically low” in the quality assessment.
Summary of findings: (2) pilot study 
on evidence‑based PET/PET–CT planning
Based on evidence-based recommended and not recom-
mended indications formulated in step (1) of this study, a 
first-ever pilot of planning PET capacities was conducted 
and, as such, has no comparator.
A data-driven needs-assessment was initially conducted 
to provide a basis for an investment decision around the need 
for an additional PET–CT scanner in Carinthia, Austria. 
First, diagnoses were coded according to ICD-10 classifica-
tions. Then, the 1762 PET scans performed between January 
and September 2017 were matched to relevant recommenda-
tions for evidence-based indications/non-indications, result-
ing in 77.8% being assigned to either recommended (54.7%), 
not recommended (1.8%) or contradictory (21.3%) evidence-
based indications. 22.2% could not be ascribed due to miss-
ing information of the diagnostic code or lack of information 
from recommendations in HTA or clinical guidelines. Based 
on the data analysis and an additional assessment of the utili-
zation as well as occupancy rates, it was decided against the 
investment in a second PET scanner in Carinthia.
Limitations
The main strength of the presented work is the rigorous, 
systematic approach applied in all steps (e.g., double-check 
principle and quality assessment), complemented a compre-
hensive, targeted manual search. Nevertheless, the methodi-
cal process has some limitations. The systematic synthe-
sis of available evidence, which mainly relies on already 
aggregated evidence, may result in a certain loss of detailed 
information. In addition, the primary outcome of interest in 
the data extraction was the conclusions as articulated by the 
respective authors, which are different in terms of formula-
tion and meaning and, therefore, difficult to compare. As a 
result, a trend can be seen in the statements.
Moreover, the multitude of recommendations from pro-
fessional organizations necessarily led to a capping of the 
number of sources, meaning that some were not included 
and important contextual insight may have been lost. For 
example, the S3 guidelines from the Association of Scien-
tific Medical Societies e.V. (AWMF) in Germany and the 
guidelines from the Scottish Intercollegiate Guidelines 
Network (SIGN) were not included as they do not have a 
specific PET/PET–CT focus. However, they both provide 
important recommendations as they consider not only “study 
evidence”, but also detailed aspects of the diagnostic-thera-
peutic chain and differentiate more comprehensively among 
tumour entities. That some guidelines were a priori omitted 
may lead to a potential bias (of the overall picture). Simi-
larly, the heterogeneous quality of the included guidelines 
may also result in a skewed overall picture of existent recom-
mendations. The summary tables make this transparent by 
assigning respective recommendations to the corresponding 
guidelines, referencing, as well, the strength of evidence. 
Finally, in Tables 2, 3, and 4 of the overall recommenda-
tions, a differentiated consideration of tumour entities is lost. 
Nevertheless, they provide an overall picture that can be 
useful (see pilot).
Regarding the 22.2% of PET scans in Carinthia, Austria, 
that could not be assigned to a recommendation in the pilot 
study, one reason could be the very specific indications found 
in the evidence or a too detailed coding. In general, while the 
high number of PET scans that could not be ascribed to any 
category could be seen as limiting the explanatory/instructive 
power of the pilot to use evidence-based indication lists as 
basis for a needs-assessment and investment decisions, it also 
shows clearly that there is a need for improvement of coding 
indications within the context of planning of medical ser-
vices. For the final investment decision, further information 
on timing and frequency of PET utilization and occupancy 
rate over full work days and weeks are needed.
Conclusion
Overall, this study has resulted in more detailed informa-
tion and specifications around PET/PET–CT indications 
as compared to the 2015 PET–HTA report. This update 
together with the aggregate list of overall recommendations 
for indications as well as the explicit non-recommendations 
from the 2015 PET–HTA report can serve as needs-based 
and evidence-based decision support for PET/PET–CT ser-
vice provision in hospitals as evidenced by the pilot study 
in Austria. A better coding of PET utilization is needed for 
planning. Furthermore, additional information such as tim-
ing, frequency of PET utilization, as well as occupancy rate 
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over full work days and weeks, is also necessary to guide an 
investment decision.
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